Published 12-05-16
Issued by CSL
Starting a century ago, CSL was driven by its promise to save lives and protect the health of people. In 2016, CSL continues to deliver on that promise through its corporate responsibility performance.
Starting a century ago, CSL was driven by its promise to save lives and protect the health of people. In 2016, CSL continues to deliver on that promise through its corporate responsibility performance. Spanning the reporting year 1 July 2015 to 30 June 2016, CSL’s key achievements and challenges include:
CSL (ASX:CSL) is a leading global biotherapeutics company with a dynamic portfolio of life-saving innovations, including those that treat haemophilia and immune deficiencies, as well as vaccines to prevent influenza. For 100 years, we have been driven by our promise to save lives using the latest technologies. Today, CSL — including our two businesses CSL Behring and Seqirus — operates in over 30 countries with more than 17,000 employees. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest.
Please visit the report website for full details of CSL’s performance and to provide feedback. For the first 100 complete survey responses received, CSL will donate AUD$50 per survey to the Hereditary Angioedema Association International (HAEi).
CSL is a global specialty biopharmaceutical company that develops, manufactures and markets therapies to prevent and treat serious human disease. CSL employs over 11,000 people and operates in 27 countries. At CSL, Corporate Responsibility is about conducting our business ethically and contributing to the economic, social and environmental well-being of our communities.